Every material Form 8-K Tonix Pharmaceuticals Holding Corp. has filed with the SEC since September 22, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Tonix Pharmaceuticals reported third-quarter 2026 net product revenue of $17.2 million, up from $3.3 million a year earlier, with TONMYA contributing $15.0 million. The net loss available to common stockholders widened to $53.3 million from $32.0 million, as research and development and selling, general and administrative expenses rose sharply. The company said its cash resources will meet its requirements into the early third quarter of 2027, a timeline shareholders will weigh against the larger losses.
Net product revenue was $17.2 million versus $3.3 million a year earlier; TONMYA net revenue was $15.0 million, up 37% from the second quarter.
Net loss available to common stockholders was $53.3 million, or $2.89 per share, compared with $32.0 million, or $3.59 per share, a year earlier.
R&D expenses were $25.8 million and SG&A expenses were $45.6 million, compared with $9.3 million and $25.7 million a year earlier.
Cash and cash equivalents were about $163 million as of September 30, 2026; the company expects them to fund operations into the early third quarter of 2027.
Tonix Pharmaceuticals disclosed preliminary, unaudited results for the quarter ended September 30, 2026, estimating TONMYA net revenue of $14.0 million to $15.0 million and cash and cash equivalents of approximately $162.8 million. The company warned that financial closing procedures are incomplete and final results could differ materially, so shareholders should treat the figures as provisional.
Estimated three-month TONMYA net revenue: $14.0 million to $15.0 million
Estimated cash and cash equivalents as of September 30, 2026: approximately $162.8 million
Figures are preliminary and subject to revision; the company has not completed financial closing procedures
Filing made under Item 2.02 with Item 8.01 incorporating the same information
On October 1, 2026, Tonix Pharmaceuticals received notice that Dr. Reddy's Laboratories had filed an ANDA with the FDA for a generic version of TONMYA, challenging four Orange Book patents. The filing matters to shareholders because it signals possible generic competition for TONMYA, and the company says it intends to vigorously enforce its intellectual property rights but cannot predict the outcome.
Notice received October 1, 2026 from Dr. Reddy's Laboratories Ltd. and Dr. Reddy's Laboratories, Inc.
ANDA covers a generic version of TONMYA (cyclobenzaprine hydrochloride) sublingual tablets, 2.8 mg, with a Paragraph IV certification
Certification targets U.S. Patent Nos. 9636408, 9956188, 10117936 and 10864175, all listed in the Orange Book
A patent infringement suit filed within 45 days of the notice would automatically block FDA approval of the ANDA for up to 30 months, subject to the outcome of litigation
Tonix announced a new pharmacy benefit manager agreement, effective immediately, that covers TONMYA for about 21 million Medicare Part D beneficiaries. The company says total commercial and government coverage for TONMYA now reaches about 166 million individuals, which expands the patients who can access the drug.
New agreement adds about 21 million Medicare lives, or 38% of about 55 million Medicare lives in the U.S.
Medicare coverage for TONMYA now totals 32 million lives, or 58% of Medicare lives in the U.S.
Total commercial and government coverage reaches about 166 million covered lives, or 53% of about 314 million total U.S. lives
Sales force totals 150 representatives after about 50 were fully activated
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Tonix Pharmaceuticals Holding Corp. filing is on SEC EDGAR ↗. 8-K briefs of other companies →